文献速递主动脉疾病

开窗腔内修复术的移植物复杂性与结局

Graft Complexity-Related Outcomes of Fenestrated Endografting for Abdominal Aortic Aneurysms.
PubMed 文献 · J Endovasc Ther · 2017-02-16

结果显示总体技术成功率95.7%,30天手术死亡率3.5%,围手术期并发症12.1%,两组的围手术期死亡率、并发症、内漏、生存率、靶血管通畅率及再干预率均无统计学显著差异。

要点

  • FEVAR治疗近肾和肾上主动脉瘤的30天死亡率为3.5%,围手术期并发症发生率为12.1%。
  • 更复杂的开窗设计(附加肠系膜上动脉和/或腹腔干开窗)未显著影响围手术期及中期结局。
  • 1年估计生存率为85.1%(95%CI 79.1%~91.1%),3年为75.8%(95%CI 68.2%~83.5%)。

核心结论

  • FEVAR用于近肾和肾上主动脉瘤具有较低的30天死亡率/并发症率和较高的中期疗效。
  • 更复杂的开窗支架设计未对围手术期和中期结果产生显著影响。

研究设计与样本

  • 回顾性研究,2006年8月至2014年12月连续纳入141例择期行FEVAR的短颈、近肾或肾上主动脉瘤患者。
  • 患者平均年龄72±7.6岁(范围50~89岁),其中男性120例。

主要发现

  • 技术成功率为95.7%(135/141)。
  • 总体30天手术死亡率为3.5%(5/141),围手术期并发症发生率为12.1%(16/141)。
  • 平均随访33±23个月,1年估计生存率85.1%(95%CI 79.1%~91.1%),3年75.8%(95%CI 68.2%~83.5%)。
  • 1年免于再干预率为90.6%(95%CI 85.6%~95.6%),3年为79.2%(95%CI 71%~87.5%)。
  • 两组在围手术期死亡率、并发症、内漏、生存率、靶血管通畅率及再干预率方面均无统计学显著差异。

临床怎么用

  • 对于近肾和肾上主动脉瘤,FEVAR是一种围手术期风险较低且中期有效的治疗选择。
  • 使用更复杂的开窗设计(附加肠系膜上动脉和/或腹腔干开窗)未增加围手术期或中期不良结局风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the outcomes of fenestrated endovascular aneurysm repair (FEVAR) and compare early and midterm results in relation to stent-graft complexity. METHODS: Between August 2006 and December 2014, 141 consecutive patients (mean age 72±7.6 years, range 50-89; 120 men) were treated electively with FEVAR for short-neck, juxtarenal, or suprarenal aortic aneurysms. Forty-five patients treated with stent-grafts featuring renal-only fenestrations were assigned to group A, while 96 patients receiving additional fenestrations for the superior mesenteric and/or celiac arteries were assigned to group B. Technical success, operative mortality and morbidity, target vessel patency, endoleak, reintervention, and survival were compared between the groups. Survival, target vessel stent patency, and reintervention during follow-up were estimated by Kaplan-Meier analysis; the estimates are presented with the 95% confidence interval (CI). RESULTS: Technical success was achieved in 135 (95.7%) patients. Overall 30-day operative mortality was 3.5% (5/141). Perioperative complications occurred in 16 (12.1%) patients. Mean follow-up was 33±23 months. Overall estimated survival was 85.1% (95% CI 79.1% to 91.1%) at 1 year and 75.8% (95% CI 68.2% to 83.5%) at 3 years. Freedom from reintervention was 90.6% (95% CI 85.6% to 95.6%) at 1 year and 79.2% (95% CI 71% to 87.5%) at 3 years. There was no statistically significant difference between the groups in terms of perioperative mortality or morbidity, endoleak, survival, target vessel patency, or reintervention. CONCLUSION: The use of FEVAR for juxta- and suprarenal aneurysms is associated with low 30-day mortality/morbidity and high midterm efficacy. So far, perioperative and midterm results are not affected by the use of more complex fenestrated designs.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Oikonomou K, Kasprzak P, Schierling W, et al. Graft Complexity-Related Outcomes of Fenestrated Endografting for Abdominal Aortic Aneurysms. J Endovasc Ther. 2017. PMID: 28205454. doi:10.1177/1526602817691752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。